GGrantIndex
← Search

High Throughput Screening/Chemical Synthesis

$180,339P30FY2014CANIH

Vanderbilt University, Nashville TN

Investigators

Linked publications, trials & patents

Trial NCT07016399Trial NCT06593106Trial NCT05501665Trial NCT05361720Trial NCT04765072Trial NCT02702310Trial NCT02685631Trial NCT02677883Trial NCT02676752Trial NCT02672475Trial NCT02658487Trial NCT02600533Trial NCT02489422Trial NCT02480114Trial NCT02457910Trial NCT02448225Trial NCT02440737Trial NCT02374931Trial NCT02359851Trial NCT02324881Trial NCT02296112Trial NCT02269111Trial NCT02240381Trial NCT02236546Trial NCT02170272Trial NCT02151539Trial NCT02148406Trial NCT01996527Trial NCT01928160Trial NCT01901367Trial NCT01660971Trial NCT01230515Trial NCT01198535Trial NCT01141218Trial NCT01098669Trial NCT01098643Trial NCT01096407Trial NCT01096394Trial NCT01096381Trial NCT01077440Trial NCT01031446Trial NCT01013506Trial NCT01009931Trial NCT01007422Trial NCT00993694Trial NCT00993135Trial NCT00987766Trial NCT00984542Trial NCT00984490Trial NCT00983268Trial NCT00957736Trial NCT00949052Trial NCT00930930Trial NCT00900406Trial NCT00900003Trial NCT00899769Trial NCT00899626Trial NCT00899457Trial NCT00899301Trial NCT00899028Trial NCT00898742Trial NCT00898638Trial NCT00898430Trial NCT00898313Trial NCT00897988Trial NCT00897832Trial NCT00897793Trial NCT00897650Trial NCT00897468Trial NCT00897403Trial NCT00897117Trial NCT00896948Trial NCT00896675Trial NCT00892801Trial NCT00875238Trial NCT00840814Trial NCT00837876Trial NCT00835679Trial NCT00801346Trial NCT00765245Trial NCT00755040Trial NCT00675636Trial NCT00670644Trial NCT00670605Trial NCT00670046Trial NCT00666211Trial NCT00656604Trial NCT00653250Trial NCT00651976Trial NCT00651716Trial NCT00647218Trial NCT00626873Trial NCT00625417Trial NCT00625066Trial NCT00616590Trial NCT00601991Trial NCT00573404Trial NCT00550537Trial NCT00544648Trial NCT00533884

Abstract

The High Throughput Screening (HTS) and Chemical Synthesis (CS) Shared Resource provides state-ofthe- art capability for Vanderbilt-lngram Cancer Center (VICC) researchers to harness the power of HTS/CS to support target discovery, pathway mapping, chemical tool discovery, and exploratory preclinical drug discovery research. HTS/CS includes a chemical library of >170,0000 small molecules, advanced liquid handling, and a broad array of signal detecfion modalifies enabling researchers to address quesfions spanning from protein-protein interactions in purified cell-free systems to colony formation and morphology assays using automated imaging. The facility has the capability of addressing all commonly used opfical techniques (fluorescence, luminscense, kinefic imaging, high-content imaging, scinfillation proximity, refractive index spectroscopy (Corning Epic), automated electrophysiology, and very shortly in collaboration with Stephen Fesik, Ph.D. fragment-based NMR approaches). The complementary CS resource provides an ability to apply advanced chemical synthesis and medicinal chemistry methodologies including solution-phase parallel synthesis, microwave assisted catalysis, automated mass-directed purification, and both chiral synthesis and purificafion resources. HTS/CS employs a highly trained staff of HTS experts who work directly with Vanderbilt investigators to develop, implement, and interpret HTS. This team works hand-in-hand with the team in the CS facility to help investigators extract maximum value from the shared resource by providing a mechanism to use medicinal chemistry techniques to understand, improve, and ufilize HTS hits. David Weaver, Ph.D., directs the HTS component and Alex Waterson, Ph.D., directs the CS portion.

View original record on NIH RePORTER →
High Throughput Screening/Chemical Synthesis · GrantIndex